Condition: Breast Cancer · Sponsor: Biotheryx, Inc.
The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where participants will receive the dose of BTX-9341 selected in Part A + fulvestrant.
This description comes directly from the study's public registry record.
Danette Powell · 858-354-1814 · c-dpowell@biotheryx.com
Always discuss trial participation with your own doctor first.
| Biotheryx Investigative Site | Rochester, Minnesota, United States | Recruiting |
| Biotheryx Investigative Site | Omaha, Nebraska, United States | Recruiting |
| Biotheryx Investigative Site | Houston, Texas, United States | Recruiting |
| Biotheryx Investigative Site | San Antonio, Texas, United States | Recruiting |
| Biotheryx Investigative Site | West Valley City, Utah, United States | Recruiting |
| Biotheryx Investigative Site | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06515470